Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.32 |
| ▸ | CDK1 | P06493 | 3/20 | 0.32 |
| ▸ | CDK4 | P11802 | 3/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.32 |
| ▸ | CCND1 | P24385 | 3/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.32 |
| ▸ | CCND2 | P30279 | 1/20 | 0.32 |
| ▸ | CCND3 | P30281 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727005 | 0.75 | CDK2 (0.32) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL9004255 | 0.75 | CDK2 (0.35) | CDK2 | |
| SCHEMBL5724820 | 0.74 | — | — | |
| SCHEMBL2616422 | 0.72 | CDK2 (0.35) | CDK2MEN1KMT2AL3MBTL1 | |
| SCHEMBL2619433 | 0.72 | PIK3CG (0.41) | CDK2 | |
| SCHEMBL21650121 | 0.71 | CNR1 (0.33) | — | |
| SCHEMBL21720208 | 0.70 | CDK2 (0.34) | CDK2L3MBTL1 | |
| SCHEMBL18647269 | 0.70 | CDK2 (0.34) | CDK2 | |
| SCHEMBL21720481 | 0.70 | CDK2 (0.34) | CDK2 | |
| SCHEMBL1979674 | 0.70 | CDK2 (0.45) | CDK2CCNE2CCNE1CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10336773-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-10011581-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011581-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180118705-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118705-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20080200552-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY (IN) | 2008-08-21 | — | — | US | disclosed |
| US-20080119407-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119407-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | CDK2 3302/4885ALOX15 3553/4885MEN1 688/4885 |
| US-20080119407-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | CDK2 2373/4885ALOX15 275/4885MEN1 3650/4885 |
| US-20080200552-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | CDK2 961/4885ALOX15 645/4885MEN1 2203/4885 |
| US-10011581-B2 | Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compound | CYP4B1, P2RX5, P2RX6 | CDK2 806/4885ALOX15 1427/4885MEN1 1499/4885 |
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | CDK2 1392/4885ALOX15 561/4885MEN1 3024/4885 |
| US-20180118705-A1 | PROCESS FOR PREPARING 4-AMINO-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-PENTANOIC ACID COMPOUND | CYP4B1, P2RX5, P2RX6 | CDK2 806/4885ALOX15 1427/4885MEN1 1499/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | CDK2 1541/4885ALOX15 542/4885MEN1 3208/4885 |
| US-10336773-B2 | Neprilysin inhibitors | MME, REN, ACE | CDK2 3302/4885ALOX15 3553/4885MEN1 688/4885 |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CDK2 3302/4885ALOX15 3553/4885MEN1 688/4885 |
| US-20200031847-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CDK2 3302/4885ALOX15 3553/4885MEN1 688/4885 |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | CDK2 2905/4885ALOX15 4060/4885MEN1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.